10-Q: Standard BioTools Reports Q1 2024 Results Following SomaLogic Merger, Revenue Jumps 81%

Standard BioTools' first quarter of 2024 saw a significant revenue increase of 81% year-over-year, primarily driven by the acquisition of SomaLogic.

Summary

• Standard BioTools reported an 81% increase in total revenue to $45.5 million for the first quarter of 2024, compared to $25.1 million in the same period of 2023.
• The revenue growth was largely due to the acquisition of SomaLogic, which contributed $23.9 million in revenue.
• The company experienced a net loss of $32.2 million, or $0.27 per share, which includes a $46 million induced conversion of redeemable preferred stock.
• Gross profit increased to $24.2 million, with a gross margin of 53.1%, up from 48.9% in the prior year.
• Operating expenses totaled $84.4 million, including $17.2 million in transaction and integration expenses related to the merger.
• The company recorded a bargain purchase gain of $25.2 million due to the fair value of net assets acquired exceeding the purchase price.
• Cash, cash equivalents, and short-term investments totaled $462.3 million as of March 31, 2024, compared to $114.9 million at the end of 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the revenue growth and merger are positive, the net loss, high operating expenses, and restructuring costs temper the overall sentiment. The company has a strong cash position, but needs to demonstrate improved cost management and integration success.

Positives

• The merger with SomaLogic significantly boosted revenue and expanded the company's proteomics capabilities.
• The company's gross margin improved to 53.1%.
• The company has a strong cash position following the merger.
• The company has a new share repurchase program in place.
• The company has repaid all outstanding debt under the Term Loan Facility.

Negatives

• The company reported a net loss of $32.2 million for the quarter.
• Operating expenses increased significantly due to the merger and restructuring costs.
• The company incurred $17.2 million in transaction and integration expenses related to the merger.
• The genomics segment experienced a 6% revenue decrease.

Risks

• The company faces risks related to the integration of SomaLogic and the realization of expected synergies.
• The company's operating expenses are high, and it needs to improve operating discipline to reduce costs.
• The company's revenue can be seasonal, dependent on customer procurement and budgeting cycles.
• The company is subject to various legal proceedings and claims, which could result in significant costs.
• The company's future performance depends on the continued adoption of its products and services.

Future Outlook

The company expects to continue to invest in R&D, improve operating discipline, and reduce costs. They anticipate that their existing liquidity and sources of capital will be sufficient to support operations for at least the next 12 months. The company also expects to incur additional transaction and integration expenses throughout 2024 related to the merger.

Management Comments

• The company's leadership team identified three strategic priorities: revenue growth, improving operating discipline, and strategic capital allocation.
• Management believes that expanding collaborative arrangements with KOLs will allow for further enhancements of the integrated platform.
• Management expects general and administrative expenses to trend downward during 2024 as they reduce headcount and realize synergies from the Merger.

Industry Context

The merger with SomaLogic positions Standard BioTools as a leading provider of multi-omics tools, aligning with the growing trend of integrating genomics and proteomics in biomedical research. The company's focus on translational and clinical research in areas like oncology, immunology, and immunotherapy reflects key areas of growth in the life sciences industry.

Comparison to Industry Standards

• The 81% revenue growth is significant, but it is largely due to the acquisition of SomaLogic, making it difficult to compare directly to organic growth rates of peers.
• The company's gross margin of 53.1% is a positive sign, but it is important to compare this to other companies in the life sciences tools and diagnostics sector, such as Illumina (ILMN) and Agilent (A), to assess its competitiveness.
• The high operating expenses, including transaction and integration costs, are expected in the short term due to the merger, but the company will need to demonstrate improved cost management to achieve profitability, similar to what is expected of other companies in the sector.
• The company's cash position of $462.3 million is strong, but it is important to monitor how this capital is deployed and whether it leads to sustainable growth and profitability, which is a key metric for investors in the life sciences sector.

Legal Proceedings

• The company is currently expecting to settle previously outstanding litigation with former shareholders of SomaLogic for $6.2 million.
• The company is involved in various legal proceedings and claims arising in the ordinary course of business, including disputes and lawsuits related to intellectual property, mergers and acquisitions, licensing, contract law, tax, regulatory, distribution arrangements, employee relations and other matters.
• The company is reviewing shareholder complaints and has not yet formally responded to them.

Related Party Transactions

• Eli Casdin, a member of the company's Board of Directors and the company's principal shareholder, and the former principal shareholder of SomaLogic, was issued shares of common stock, restricted stock units, and options in exchange for his shares of SomaLogic Common Stock and SomaLogic equity awards.
• Casdin Partners Master Fund, L.P. and Casdin Private Growth Equity Fund, L.P. received shares of common stock in exchange for their shares of SomaLogic Common Stock.
• Warrants held by CMLS Holdings II LLC (CMLS LLC) converted into the right to receive shares of the company's common stock and CMLS LLC also received shares of common stock in exchange for its SomaLogic Common Stock.
• On March 18, 2024, Casdin and its affiliates entered into the Exchange Agreement with the Company whereby all of the outstanding shares of the Series B-1 Preferred Stock held by Casdin and its affiliates were converted into shares of the Company's common stock.

Stakeholder Impact

• Shareholders will be impacted by the increased revenue and potential for future growth, but also by the net loss and restructuring costs.
• Employees will be impacted by the reduction in force and restructuring plan.
• Customers will benefit from the expanded product and service offerings resulting from the merger.
• Suppliers may be impacted by changes in the company's supply chain and manufacturing footprint.
• Creditors will be impacted by the company's debt repayment and financial performance.

Next Steps

• The company plans to continue to invest in R&D.
• The company plans to improve operating discipline.
• The company plans to reduce costs.
• The company expects to incur additional transaction and integration expenses throughout 2024.
• The company will continue to accrue liabilities for restructuring charges primarily related to employee severance throughout 2024.

Key Dates

Keywords

SomaLogic, Merger, Proteomics, Genomics, Revenue Growth, Financial Results, Share Repurchase, Operating Expenses, Bargain Purchase Gain, Convertible Notes